Once-Monthly Darbepoetin alfa for Maintaining Hemoglobin Levels in Older Patients With Chronic Kidney Disease

Journal of the American Medical Directors Association

Volumn 8, Issue 2, 2007, Pages 83-90

  Agarwal, Anil ^a   Silver, Marcia R ^b   Walczyk, Michael ^c   Liu, Wei ^d   Audhya, Paul ^d  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c Northwest Renal Clinic   (United States)

^d AMGEN INC   (United States)

Author keywords

anemia; Chronic kidney disease; darbepoetin alfa; extended dosing

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; ELDERLY CARE; EPISTAXIS; ERYTHEMA MULTIFORME; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INJECTION SITE PAIN; IRON DEFICIENCY; IRON THERAPY; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

EID: 33846654468     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.07.007     Document Type: Article

References (40)

1. Brown W.W., Peters R.M., Ohmit S.E., et al. Early detection of kidney disease in community settings: The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 42 (2003) 22-35
2. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
3. Garg A.X., Papaioannou A., Ferko N., et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 65 (2004) 649-653
4. Papaioannou A., Ray J.G., Ferko N.C., et al. Estimation of creatinine clearance in elderly persons in long-term care facilities. Am J Med 111 (2001) 569-573
5. He W., Sengupta M., Velkoff V.A., et al. 65+ in the United States: 2005. Current Population Reports, Special Studies (2005), U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Aging. http://www.census.gov/prod/2006pubs/p23-209.pdf Issued December Available at: http://www.census.gov/prod/2006pubs/p23-209.pdf. Accessed April 5, 2006.
6. Eckardt K.U., and Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 35 Suppl 3 (2005) 13-19
7. Li S., Foley R.N., and Collins A.J. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol 37 (2005) 395-402
8. Narayanan S., Critchlow C., Sciarra A., et al. Chronic kidney disease (CKD)-associated anemia is common in elderly nursing-home residents. [abstract]. J Am Soc Nephrol 16 (2005) 549A
9. Fried L.F., Shlipak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 41 (2003) 1364-1372
10. Fried L.F., Katz R., Sarnak M.J., et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 16 (2005) 3728-3735
11. Zakai N.A., Katz R., Hirsch C., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Arch Intern Med 165 (2005) 2214-2220
12. Izaks G.J., Westendorp R.G., and Knook D.L. The definition of anemia in older persons. JAMA 281 (1999) 1714-1717
13. Collins A.J., Li S., Gilbertson D.T., et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 87 (2003) S24-S31
14. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
15. Herzog C.A., Muster H.A., Li S., et al. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 10 (2004) 467-472
16. Jurkovitz C.T., Abramson J.L., Vaccarino L.V., et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 14 (2003) 2919-2925
17. Astor B.C., Coresh J., Heiss G., et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 151 (2006) 492-500
18. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
19. Levin A., Djurdjev O., Duncan J., et al. Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 21 (2006) 370-377
20. Egrie J.C., Dwyer E., Browne J.K., et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31 (2003) 290-299
21. Elliott S., Lorenzini T., Asher S., et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21 (2003) 414-421
22. Macdougall I.C., Gray S.J., Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 (1999) 2392-2395
23. Padhi D., Ni L., Cooke B., et al. An extended terminal half-life for darbepoetin alfa: Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 45 (2006) 503-510
24. Suranyi M.G., Lindberg J.S., Navarro J., et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23 (2003) 106-111
25. Toto R.D., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24 (2004) 453-460
26. Ling B., Walczyk M., Agarwal A., et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63 (2005) 327-334
27. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
28. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
29. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
30. Gouva C., Nikolopoulos P., Ioannidis J.P., et al. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int 66 (2004) 753-760
31. Jungers P., Choukroun G., Oualim Z., et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 16 (2001) 307-312
32. Dean B.B., Dylan M., Gano Jr. A., et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 21 (2005) 981-987
33. Portoles J., Torralbo A., Martin P., et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29 (1997) 541-548
34. Hayashi T., Suzuki A., Shoji T., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35 (2000) 250-256
35. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
36. Provenzano R., Garcia-Mayol L., Suchinda P., et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 61 (2004) 392-405
37. Hertel J., Locay H., Scarlata D., et al. Every-other-week Aranesp(R) (darbepoetin alfa) achieves and maintains target hemoglobin (Hb) levels and improves health-related quality of life (HRQOL) in recombinant human erythropoietin (rHuEPO)-naive patients with chronic kidney disease (CKD). [abstract]. J Am Soc Nephrol 16 (2005) 547A
38. Locatelli F., Olivares J., Walker R., et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60 (2001) 741-747
39. Bernardo M., Hertel J., Xu X., et al. Comparison of practice resources required to provide weekly (QW) versus monthly (QM) erythropoiesis stimulating protein (ESP) therapy. [abstract]. Am J Kidney Dis 47 (2006) A18
40. Hertel J., Crawford P., Mafilios M., et al. Cost minimization model evaluating resource utilization to nephrology practices treating patients with erythropoietic stimulating protein (ESP) on a monthly (QM) versus weekly (QW) basis. [abstract]. Am J Kidney Dis 47 (2006) A34